A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
← catalyst calendarNCT05531656 · readout in 284 d
Sponsored by Cognition Therapeutics (industry) · CGTX — their whole pipeline →. With National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
540estimated
Sites
50
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-28 | actual | When the study began enrolling |
| Primary completion | 2027-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early Alzheimer's Disease
Interventions
- Drug: CT1812 — also filed as Study Drug Active
- Drug: Placebo — also filed as Matching Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale.
measured 18 months
Permalink · CGTX's whole pipeline · Catalyst calendar · Every registered study · What changed